Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 May 24;14(11):2591.
doi: 10.3390/cancers14112591.

Prognostic Impact of Microscopic Extra-Thyroidal Extension (mETE) on Disease Free Survival in Patients with Papillary Thyroid Carcinoma (PTC)

Affiliations

Prognostic Impact of Microscopic Extra-Thyroidal Extension (mETE) on Disease Free Survival in Patients with Papillary Thyroid Carcinoma (PTC)

Nadia Bouzehouane et al. Cancers (Basel). .

Abstract

Background: This study assessed the risk of reduced disease-free survival (DFS) and poor clinical outcome in patients with papillary thyroid carcinomas (PTC) with microscopic extra-thyroidal extension (mETE), as compared to PTC patients without mETE. Methods: Retrospective analysis of a prospective database of patients treated by total thyroidectomy and radioactive iodine (RAI) with a five-year follow-up and tumors < 40 mm. In total, 303 patients were analyzed: 30.7% presented tumors with mETE, and 69.3% without. mETE was defined as extra-thyroidal invasion without skeletal muscle involvement. The primary outcome, DFS, was defined as the interval between initial treatment and any subsequent PTC-related treatment. The second outcome was the clinical status at five years. Results: In univariate analyses, the five-year DFS was significantly lower for tumors with mETE (62.4% versus 88.1%, p < 0.001). In multivariate analysis, mETE and massive lymph node involvement (LNI) were independent prognostic factors, associated respectively with a hazard ratio of 2.55 (95% CI 1.48−4.40) and 8.94 (95% CI 4.92−16.26). mETE was significantly associated with a pejorative clinical outcome at five years, i.e., biochemical/indeterminate response and structural persistence (Respectively OR 1.83 (95% CI 0.83; 4.06) and OR 4.92 (95% CI 1.87; 12.97)). Conclusion: Our results suggest that mETE is an independent poor prognosis factor of reduced DFS and predictive of poor clinical outcome.

Keywords: microscopic extra-thyroidal extension; papillary thyroid carcinoma.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
Univariate analysis (Kaplan-Meier analysis). (A). Recurrence-free survival (RFS) in patients with mETE vs. no mETE. (B). RFS in patients with aggressive histology vs. no aggressive histology carcinoma. (C). RFS in patients with pathological margin resection (R1) vs. no pathological margin resection. (D). RFS in patients with LNI (N1b or N1a) vs. no LNI (N0-Nx).

References

    1. Bhattacharyya N. A Population-Based Analysis of Survival Factors in Differentiated and Medullary Thyroid Carcinoma. Otolaryngol. Head Neck Surg. 2003;128:115–123. doi: 10.1067/mhn.2003.2. - DOI - PubMed
    1. Veiga L., Neta G., Aschebrook-Kilfoy B., Ron E., Devesa S. Thyroid Cancer Incidence Patterns in Sao Paulo, Brazil, and the U.S. SEER Program, 1997–2008. Thyroid. 2013;23:748–757. doi: 10.1089/thy.2012.0532. - DOI - PMC - PubMed
    1. Shah J.P., Loree T.R., Dharker D., Strong E.W., Begg C., Vlamis V. Prognostic factors in differentiated carcinoma of the thyroid gland. Am. J. Surg. 1992;164:658–661. doi: 10.1016/S0002-9610(05)80729-9. - DOI - PubMed
    1. Tuttle R.M., Haugen B., Perrier N.D. Updated American Joint Committee on Cancer/Tumor-Node- Metastasis Staging System for Differentiated and Anaplastic Thyroid Cancer (8th ed.): What Changed and Why? Thyroid. 2017;27:751–756. doi: 10.1089/thy.2017.0102. - DOI - PMC - PubMed
    1. Xing M. Genetic-guided Risk Assessment and Management of Thyroid Cancer. Endocrinol. Metab. Clin. N. Am. 2019;48:109–124. doi: 10.1016/j.ecl.2018.11.007. - DOI - PMC - PubMed

LinkOut - more resources